Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies.
The recent application of antiangiogenic therapies has opened a new corridor of treatment in metastatic renal cell carcinoma. These therapies influence intracellular pathways that are important in angiogenesis and tumor progression. Although each of these agents produces objective responses as well as progression-free survival benefits, durable complete responses have not generally been observed, and thus, resistance to these chronic therapies is almost universal. The increasing use and eventual resistance to these agents has defined an increasing population of patients with targeted therapy-refractory disease. However, there are limited clinical and preclinical data to guide treatment decisions for these patients. This review will examine the existing data in this setting, describe ongoing clinical investigations, and discuss challenges unique to this patient population.
George
Saby
S
Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA.
Rini
Brian I
BI
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents